Effects of aliskiren on hemodynamic parametersin daunorubicin -induced acute cardiomyopathy in rats

Abstract

Daunorubicin ((DNR)) used in oncological practice against a wide variety of solid organ tumors and hematologic malignancies, including leukemia, lymphoma, breast cancer, lung cancer, multiple myeloma and sarcoma. however clinical use of this agent is limited due to cardiomyopathy and cardiac heart failure. one of the important player in the development of cardic hypertrophy and reperfusion injury is reninangiotensin system. Aliskiren (ALK) a recent drug of a direct inhibitor of the renin enzyme. It Protect cardiomyopathy by the inhibition of the renin activity. Present study is towards the evaluation of protective effcets of ALK 50 and 100 mg/kg/day in rats. The systolic, diastolic, mean BP and heart rate were significantly (P< 0.01) increased in DNR control group as compared to normal control group. Thus the results provide clear evidence that the ALK pretreatment offered significant protection against DNR-induced Hemodynamic parameters changes.